DE60111622D1 - Getrennte dosis therapien mit gefässschädigender aktivität - Google Patents

Getrennte dosis therapien mit gefässschädigender aktivität

Info

Publication number
DE60111622D1
DE60111622D1 DE60111622T DE60111622T DE60111622D1 DE 60111622 D1 DE60111622 D1 DE 60111622D1 DE 60111622 T DE60111622 T DE 60111622T DE 60111622 T DE60111622 T DE 60111622T DE 60111622 D1 DE60111622 D1 DE 60111622D1
Authority
DE
Germany
Prior art keywords
vulnerable
activity
vascular damaging
dose therapies
isolated dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60111622T
Other languages
English (en)
Other versions
DE60111622T2 (de
Inventor
Peter David Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogene Pharmaceuticals Ltd
Original Assignee
Angiogene Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharmaceuticals Ltd filed Critical Angiogene Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60111622D1 publication Critical patent/DE60111622D1/de
Publication of DE60111622T2 publication Critical patent/DE60111622T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60111622T 2000-03-31 2001-03-27 Getrennte dosis therapien mit gefässschädigender aktivität Expired - Fee Related DE60111622T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0007740 2000-03-31
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0013928 2000-06-08
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
GB0014904 2000-06-20
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (2)

Publication Number Publication Date
DE60111622D1 true DE60111622D1 (de) 2005-07-28
DE60111622T2 DE60111622T2 (de) 2006-05-18

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111622T Expired - Fee Related DE60111622T2 (de) 2000-03-31 2001-03-27 Getrennte dosis therapien mit gefässschädigender aktivität

Country Status (23)

Country Link
US (1) US20030055024A1 (de)
EP (1) EP1272200B1 (de)
JP (1) JP2003528921A (de)
KR (1) KR20020084267A (de)
CN (1) CN1422157A (de)
AT (1) ATE298240T1 (de)
AU (2) AU2001242586B2 (de)
BR (1) BR0109671A (de)
CA (1) CA2402078A1 (de)
CZ (1) CZ20023231A3 (de)
DE (1) DE60111622T2 (de)
EE (1) EE200200549A (de)
ES (1) ES2243466T3 (de)
HU (1) HUP0300576A3 (de)
IL (1) IL151627A0 (de)
IS (1) IS6555A (de)
MX (1) MXPA02009603A (de)
NO (1) NO20024683L (de)
NZ (1) NZ534190A (de)
PL (1) PL357282A1 (de)
PT (1) PT1272200E (de)
SK (1) SK13902002A3 (de)
WO (1) WO2001074369A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
US20060142239A1 (en) * 2003-06-18 2006-06-29 Ryan Anderson J Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
US5326905A (en) * 1990-04-02 1994-07-05 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
AU5717400A (en) * 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
NO20024683D0 (no) 2002-09-30
ES2243466T3 (es) 2005-12-01
AU4258601A (en) 2001-10-15
CN1422157A (zh) 2003-06-04
KR20020084267A (ko) 2002-11-04
CZ20023231A3 (cs) 2003-01-15
NZ534190A (en) 2007-05-31
ATE298240T1 (de) 2005-07-15
HUP0300576A3 (en) 2005-02-28
US20030055024A1 (en) 2003-03-20
BR0109671A (pt) 2003-02-04
NO20024683L (no) 2002-10-15
PT1272200E (pt) 2005-09-30
WO2001074369A1 (en) 2001-10-11
DE60111622T2 (de) 2006-05-18
EP1272200A1 (de) 2003-01-08
AU2001242586B2 (en) 2004-12-16
PL357282A1 (en) 2004-07-26
SK13902002A3 (sk) 2003-05-02
IS6555A (is) 2002-10-18
EE200200549A (et) 2004-02-16
EP1272200B1 (de) 2005-06-22
HUP0300576A2 (hu) 2003-07-28
CA2402078A1 (en) 2001-10-11
JP2003528921A (ja) 2003-09-30
IL151627A0 (en) 2003-04-10
MXPA02009603A (es) 2004-05-14

Similar Documents

Publication Publication Date Title
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
CY1110376T1 (el) Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
EA200100088A1 (ru) Готовая препаративная форма в виде микрочастиц для ингаляции
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
NO20032027L (no) Effektive antitumorbehandlinger
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
NZ507203A (en) Use of dexmedetomidine for ICU sedation
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
DE60111622D1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
NO20043774L (no) The use of devazenide as analgesic agent
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
RU2003110183A (ru) Способ лечения рассеянного склероза
BR0315087A (pt) Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina
TH60393A (th) การบัดบัดรักษาอาการเจ็บปวด

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee